Konstantinos Afratis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Konstantinos Afratis has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Abhijeet Kapoor
National Center for Advancing Translational Sciences, NIH
2 shared publicationsAmy Wang
National Center for Advancing Translational Sciences, NIH
2 shared publications- Juan Jose Marugan
National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
2 shared publications Marc Ferrer
National Center for Advancing Translational Sciences, NIH
2 shared publications- Noel Southall
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
2 shared publications - Pranav Shah
National Center for Advancing Translational Sciences, NIH
2 shared publications
Latest Publications
- Open Access
- 20 November 2026
- Published by American Chemical Society (ACS) in ACS Omega
Structure–Activity Relationship of N-(2-(Piperidin-1-yl)phenyl)benzene-1,4-disulfonamides as TRPML1 Agonists
Transient receptor potential mucolipin 1 (TRPML1) is a lysosomal Ca2+ channel that regulates lysosomal trafficking, autophagy, and membrane repair. Its pharmacological activation represents a promising strategy for treating lysosomal dysfunction-related diseases, including lysosomal storage disorders, neurodegenerative diseases, muscular dystrophies, infectious diseases, and inflammatory disorders. However, existing TRPML1 agonists suffer from limitations that restrict their utility as in vivo probes and therapeutic leads. We report a comprehensive structure–activity relationship (SAR) study of N-(2-(piperidin-1-yl)phenyl)benzene-1,4-disulfonamides that delivered potent, selective, and pharmacokinetically improved TRPML1 agonists. Systematic scaffold optimization revealed key structural determinants of channel activation, yielding substantial potency gains alongside improved physicochemical, metabolic, and pharmacokinetic properties. Refinement of the aryl sulfonamide substituents and piperidine-containing moieties established clear SAR trends that enhanced cellular activity. Lead compounds exhibited robust TRPML1 agonism, high selectivity over related TRP channels, and in vivo-compatible pharmacokinetics. These studies validate this scaffold as a privileged chemotype for TRPML1 activation, providing optimized chemical probes for investigating TRPML1 biology and a foundation for therapeutic development across multiple indications.
- 20 November 2026
- Published by American Chemical Society (ACS) in ACS Omega
Open AccessStructure–Activity Relationship of N-(2-(Piperidin-1-yl)phenyl)benzene-1,4-disulfonamides as TRPML1 Agonists
Transient receptor potential mucolipin 1 (TRPML1) is a lysosomal Ca2+ channel that regulates lysosomal trafficking, autophagy, and membrane repair. Its pharmacological activation represents a promising strategy for treating lysosomal dysfunction-related diseases, including lysosomal storage disorders, neurodegenerative diseases, muscular dystrophies, infectious diseases, and inflammatory disorders. However, existing TRPML1 agonists suffer from limitations that restrict their utility as in vivo probes and therapeutic leads. We report a comprehensive structure–activity relationship (SAR) study of N-(2-(piperidin-1-yl)phenyl)benzene-1,4-disulfonamides that delivered potent, selective, and pharmacokinetically improved TRPML1 agonists. Systematic scaffold optimization revealed key structural determinants of channel activation, yielding substantial potency gains alongside improved physicochemical, metabolic, and pharmacokinetic properties. Refinement of the aryl sulfonamide substituents and piperidine-containing moieties established clear SAR trends that enhanced cellular activity. Lead compounds exhibited robust TRPML1 agonism, high selectivity over related TRP channels, and in vivo-compatible pharmacokinetics. These studies validate this scaffold as a privileged chemotype for TRPML1 activation, providing optimized chemical probes for investigating TRPML1 biology and a foundation for therapeutic development across multiple indications.
- 19 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5956-5985
Structure–Activity Relationship Studies toward the Optimization of First-In-Class Selective Small Molecule Agonists of the GPCR Relaxin/Insulin-like Family Peptide Receptor 2
A dose-response quantitative high-throughput screening of 147,334 small molecule compounds using a human Relaxin/Insulin-like Family Peptide Receptor 2 (RXFP2)-transfected HEK293T-RXFP2 cell line identified compound 5 with modest Insulin-Like3 (INSL3) agonist activity. An extensive structure-activity relationship (SAR) study was undertaken to improve potency, efficacy, and physical/metabolic properties of the series, resulting in the discovery of compound 68. This compound represents the first-in-class small molecule full agonist of RXFP2 that exhibits nanomolar potency and favorable pharmacokinetic characteristics, including high systemic exposure in vivo. Based on these findings, compound 68 was selected as the lead preclinical candidate for investigating the role of RXFP2 activation in bone remodeling and other physiological systems in vitro and in vivo.
- 19 February 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (5) , 5956-5985
Structure–Activity Relationship Studies toward the Optimization of First-In-Class Selective Small Molecule Agonists of the GPCR Relaxin/Insulin-like Family Peptide Receptor 2
A dose-response quantitative high-throughput screening of 147,334 small molecule compounds using a human Relaxin/Insulin-like Family Peptide Receptor 2 (RXFP2)-transfected HEK293T-RXFP2 cell line identified compound 5 with modest Insulin-Like3 (INSL3) agonist activity. An extensive structure-activity relationship (SAR) study was undertaken to improve potency, efficacy, and physical/metabolic properties of the series, resulting in the discovery of compound 68. This compound represents the first-in-class small molecule full agonist of RXFP2 that exhibits nanomolar potency and favorable pharmacokinetic characteristics, including high systemic exposure in vivo. Based on these findings, compound 68 was selected as the lead preclinical candidate for investigating the role of RXFP2 activation in bone remodeling and other physiological systems in vitro and in vivo.
- 1 January 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 210, 112948
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
- 1 January 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 210, 112948
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?